Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 4/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 7/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 7/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3410142 | 0.88 | HTR1A (0.42) | HTR2AADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL3415182 | 0.83 | HTR1A (0.47) | ABCG2HTR1A | |
| SCHEMBL4100569 | 0.82 | DOT1L (0.41) | — | |
| SCHEMBL4115052 | 0.82 | MAPT (0.39) | — | |
| SCHEMBL4100574 | 0.81 | MAPT (0.37) | — | |
| SCHEMBL3401615 | 0.80 | PFKFB3 (0.40) | XIAPEGFRHTR1A | |
| SCHEMBL3404302 | 0.80 | BACE1 (0.37) | XIAPHTR2AHTR1A | |
| SCHEMBL4111414 | 0.79 | HCRTR1 (0.40) | — | |
| SCHEMBL4104133 | 0.78 | HTR1A (0.37) | ADRA1DADRA1AADRA1BEGFRHTR1A | |
| SCHEMBL4103866 | 0.77 | HTR1A (0.39) | ADRA1DADRA1AADRA1BEGFRHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188284-B2 | 2-aminoquinolines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2252372-A1 | 2-AMINOQUINOLINES | F. Hoffmann-La Roche AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009109502-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227583-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227583-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2B | XIAP 2852/4885HTR2A 4/4885ADRA1D 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.